Atomic resolution crystal structures of HIV‐1 protease and mutants V82A and I84V with saquinavir
暂无分享,去创建一个
Irene T Weber | Robert W Harrison | Yuan-Fang Wang | Arun K. Ghosh | I. Weber | R. Harrison | A. Kovalevsky | J. Tőzsér | Y. Tie | P. Boross | Arun K Ghosh | Peter Boross | Yunfeng Tie | Jozsef Tozser | Andrey Y Kovalevsky | Yuan‐Fang Wang
[1] Rational approaches to resistance: using saquinavir. , 1996, AIDS.
[2] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[3] M Karplus,et al. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. , 2002, Journal of molecular biology.
[4] J S Mills,et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.
[5] A Wlodawer,et al. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.
[6] C. Debouck,et al. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease. , 1998, Biochemistry.
[7] Irene T Weber,et al. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. , 2006, Journal of molecular biology.
[8] Ursula Rothlisberger,et al. Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.
[9] J. Louis,et al. Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. , 1996, Biochemistry.
[10] A. Velázquez‐Campoy,et al. HIV-1 protease inhibitors: enthalpic versus entropic optimization of the binding affinity. , 2000, Biochemistry.
[11] M. Hatada,et al. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.
[12] R M Esnouf,et al. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.
[13] J. Louis,et al. Chemical synthesis and expression of the HIV-1 protease gene in E. coli. , 1989, Biochemical and biophysical research communications.
[14] Arun K. Ghosh,et al. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. , 2006, Journal of medicinal chemistry.
[15] J. Louis,et al. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. , 1999, Structure.
[16] I. Weber,et al. Development of a microtiter plate fluorescent assay for inhibition studies on the HTLV-1 and HIV-1 proteinases. , 2004, Journal of virological methods.
[17] Irene T. Weber,et al. Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro , 2003, Antimicrobial Agents and Chemotherapy.
[18] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[19] M. Ott,et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. , 1996, The Journal of infectious diseases.
[20] S. Gulnik,et al. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.
[21] L. Bacheler,et al. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. , 1998, Biochemistry.
[22] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[23] L Hong,et al. Crystal structure of an in vivo HIV‐1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance , 2000, Protein science : a publication of the Protein Society.
[24] Irene T Weber,et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. , 2005, Journal of molecular biology.
[25] T. Chou,et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication , 1996, Antimicrobial agents and chemotherapy.
[26] Michele Parrinello,et al. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. , 2002, Journal of molecular biology.
[27] A. Wlodawer,et al. Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.
[28] H. B. Schock,et al. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. , 2000, Acta crystallographica. Section D, Biological crystallography.
[29] Irene T Weber,et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. , 2004, Journal of molecular biology.
[30] J. Navaza,et al. AMoRe: an automated package for molecular replacement , 1994 .
[31] H. B. Schock,et al. Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors* , 1999, The Journal of Biological Chemistry.
[32] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[33] Irene T Weber,et al. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. , 2004, European journal of biochemistry.
[34] C. Schiffer,et al. Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy , 2003, Journal of Virology.
[35] Celia A. Schiffer,et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor , 2004, Journal of Virology.
[36] Irene T Weber,et al. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. , 2006, Journal of molecular biology.
[37] R M Stroud,et al. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. , 1998, Biochemistry.
[38] G. Sheldrick,et al. SHELXL: high-resolution refinement. , 1997, Methods in enzymology.
[39] P. Massip,et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV‐1 infection , 2000, Journal of medical virology.
[40] J. Tözsér,et al. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. , 2003, Current pharmaceutical design.
[41] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[42] Irene T Weber,et al. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV‐1 protease mutants with substrate analogs , 2005, The FEBS journal.
[43] I B Duncan,et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. , 1995, Virology.